HPTX (MM)

Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Hyperion Therapeutics, Inc. ("Hyperion” or "the Company") (Nasdaq:HPTX) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Horizon Pharma plc. (“Horizon”).

Click here to learn more about the investigation http://brodsky-smith.com/911-hptx-hyperion-therapeutics-inc.html, or call: 877-534-2590. There is no cost or obligation to you.

Under the terms of the transaction, Hyperion shareholders will receive only $46.00 in cash for each share of Hyperion stock they own. The investigation concerns whether the Board of Hyperion breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether Horizon is underpaying for Hyperion. The transaction may undervalue Hyperion which manufactures the drug Ravicti, a treatment for Urea Cycle disorder. The FDA approved Ravicti in 2013 and the drug has annual sales of $105 million. However, Hyperion has estimated that Urea Cycle disorder is substantially under diagnosed providing ample room for growth. As a result, an analyst has set a $52.00 per share price target for Hyperion stock and following the announcement Horizon stock was up 18%.

If you own shares of Hyperion stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 510, Bala Cynwyd, PA 19004, by visiting http://brodsky-smith.com/911-hptx-hyperion-therapeutics-inc.html, or calling toll free 877-LEGAL-90.

Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.

Brodsky & Smith, LLCJason L. Brodsky, EsquireEvan J. Smith, Esquire877-LEGAL-90http://brodsky-smith.com/911-hptx-hyperion-therapeutics-inc.html

(MM) (NASDAQ:HPTX)
Historical Stock Chart
From Nov 2024 to Dec 2024

(MM) (NASDAQ:HPTX)
Historical Stock Chart
From Dec 2023 to Dec 2024